大剂量艾迪注射液配合TCF方案治疗进展期胃癌疗效观察

Study of chemotherapy combined with Aidi injection in treatment of advanced gastric cancer

目的比较大剂量艾迪注射液联合TCF化疗方案与单纯TCF方案对进展期胃癌的疗效、毒副作用及生存质量评分。方法A组应用Taxol＋DDP＋5-Fu方案化疗同时联合艾迪注射液80～100mL／（次·d），B组单用TaXOl＋DDP＋5Fu方案。21d为1个周期，连用2个周期后评价疗效。结果A组有效13例（54％），B组有效10例（43％），2组近期疗效比较无显著性差异（P〉0．05）。A组的Ⅲ＋Ⅳ度白细胞抑制毒性及消化道反应均低于B组（P均〈0．05）。A组生存质量评分提高率明显高于B组（P〈0．05）。结论大剂量艾迪注射液配合TCF方案治疗进展期胃癌，能降低化疗毒副作用，提高患者生存质量。

Objective It is to compare the therapeutic effect, adverse reaction and prognosis in paclitaxel plus cisplatin and 5 FU of chemotherapy combined with Aidi injection with those of chemotherapy alone in patients with advanced gastric cancer. Methods In group A, in the same time of TCF chemotherapy, Aidi injection （80 to 100 mL） was given intravenously on days 1 21. There was only TCF chemotherapy in group B. Each cycle consisting for 21 days with at least 2 cycles administered for one course. Results The effective rates in group A and group B were 54.2 % （13/24） and 43.5 % （10/23） respectively. There was no significant difference of overall response rate between two groups （ P 〉 0.05）. Ⅲ ＋ Ⅳ leukocyte suppression and gastrointestinal reaction were lower in group A than that in group B （P 〈 0.05）. The improvement of QOL in group A was higher than that in group B （P 〈 0.05）. Conclusion TCF chemotherapy combined with Aidi injection can reduce the adverse reaction of chemotherapy and improve patients＇ quality of life （QOL） in patients with advanced gastric cancer.